Showing 521 - 540 results of 2,299 for search 'Patient Number 9', query time: 0.09s Refine Results
  1. 521
  2. 522
  3. 523

    Anxiety as a mediator between symptom distress and quality of life in peritoneal dialysis patients: insights from mediation analysis and nonlinear models by Sixia Chen, Yun Wang, Sheng Feng, Mingli Shen, Fan Zhang, Kai Song, Wenwen Li, Yun- Wang

    Published 2025-12-01
    “…Anxiety mediated these relationships significantly, explaining 38.9% (95%CI: 18%–62%) and 33.3% (95%CI: 19%–49%) of the total effects for symptom number and distress, respectively. …”
    Get full text
    Article
  4. 524

    Behavior of SD-OCT Detectable Hyperreflective Foci in Diabetic Macular Edema Patients after Therapy with Anti-VEGF Agents and Dexamethasone Implants by Anne Rübsam, Laura Wernecke, Saskia Rau, Dominika Pohlmann, Bert Müller, Oliver Zeitz, Antonia M. Joussen

    Published 2021-01-01
    “…The number of foci decreased in 62.5% of patients after anti-VEGF (130.6 vs. 111.1, p=0.07) and in 68% of patients after dexamethasone injection ((123.4 vs. 94.9, p=0.02) 5.1). …”
    Get full text
    Article
  5. 525
  6. 526

    Three-Year Outcomes of Patients with Neovascular Age-Related Macular Degeneration Treated with Aflibercept under the National Health Insurance Program in Taiwan by Kang-Jung Lo, Jin-Yu Chang, Hsin-Yi Chang, Shih-Hwa Chiou, De-Kuang Hwang, Shih-Jen Chen

    Published 2020-01-01
    “…Ninety-nine eyes in 99 patients were followed up for 3 years. The mean age at onset of nAMD was 82.8 ± 9.26 years, and 65% of the patients were male. …”
    Get full text
    Article
  7. 527
  8. 528
  9. 529
  10. 530

    A retrospective study on potential drug‒drug interactions in patients with severe asthma receiving biological therapy: a single-center experience by Mirna Momcilovic, Petra Turcic, Franka Butkovic, Sanja Popovic Grle

    Published 2025-01-01
    “…Interactions of level C, D and X were recorded in, as follows: 83.33%, 25% and 33.33% patients with an average of 4.66, 1.53 and 1.9 interactions per patient. …”
    Get full text
    Article
  11. 531

    Cardioprotective effect of crocin in patients with breast cancer receiving anthracycline-based chemotherapy: A randomized, double-blind, placebo-controlled study by Xinye Li, Xin Su, Wanping Liang, Li Wang, Chao Yuan, Juping Xu, Yijun Zhang, Yan Liu, Ning Ma, Fan Yang, Yiyuan Yang, Liyuan Tao, Shipeng Sun, Hongcai Shang, Yanwei Xing

    Published 2025-03-01
    “…Anthracycline chemotherapy leads to cardiotoxicity in patients with breast cancer. We performed a double-blind randomized controlled trial to assess the efficacy of crocin (crocin tablets) in reducing anthracycline-induced cardiotoxicity in breast cancer patients. …”
    Get full text
    Article
  12. 532
  13. 533
  14. 534
  15. 535
  16. 536

    Large Rearrangements in Genes Responsible for Familial Adenomatous Polyposis, <i>MUTYH</i>-Associated Polyposis and Peutz–Jeghers Syndrome in Russian Patients by A. N. Loginova, Yu. A. Shelygin, V. P. Shubin, A. M. Kuzminov, D. Yu. Pikunov, T. A. Saveleva, A. S. Tsukanov

    Published 2023-06-01
    “…Seven large deletions and one large duplication in the APC gene were identified in 83 patients with classic familial adenomatous polyposis, with rate of large rearrangements 9.6 % (8/83). …”
    Get full text
    Article
  17. 537

    Prevalence and predictors of permanent pacemaker implantation in patients with aortic stenosis undergoing transcatheter aortic valve implantation: a prospective cohort study by Erlend Eriksen, Ronak Rajani, Sahrai Saeed, Svein Rotevatn, Daanyaal Wasim, Øyvind Bleie, Abukar Mohamed Ali, Erik Jerome Stene Packer, Håvard Keilegavlen

    Published 2025-02-01
    “…Among the 548 eligible patients, 173 (31.6%) underwent pacemaker implantation ≤30 days following TAVI, evenly distributed between females and males (29.6% vs 33.6%, p=0.317), with higher implant rates at low-volume phase (2012–2015) and lower implant rates at high-volume phase (2016–2019) (45.8% vs 23.9%, p&lt;0.001). …”
    Get full text
    Article
  18. 538

    Validation of a delirium predictive model in patients admitted to surgical intensive care units: a multicentre prospective observational cohort study by Kaweesak Chittawatanarat, Onuma Chaiwat, Sirirat Mueankwan, Sunthiti Morakul, Pitchaya Dilokpattanamongkol, Chayanan Thanakiattiwibun, Arunotai Siriussawakul

    Published 2022-06-01
    “…The optimum cut-off value to discriminate between a high and low probability of postoperative delirium in SICU patients was 115. This cut-off offered the highest value for Youden’s index (0.50), the best AUROC, and the optimum values for sensitivity (78.9%) and specificity (70.9%).Conclusions The model developed by the previous study was able to predict the occurrence of postoperative delirium in critically ill surgical patients admitted to SICUs.Trial registration number Thai Clinical Trail Registry (TCTR20180105001).…”
    Get full text
    Article
  19. 539

    Evaluating the antagonist effect of naltrexone implant via opioid challenge tests with escalating doses of hydromorphone injection in former heroin dependent patients by Wei Qu, Xuyi Wang, Chongyang Dong, Tao Zhang, Shugui Yin, Zhijun Sun, Shiqiang Wang, Anni Guo, Wei Hao

    Published 2025-01-01
    “…Thirty-one former opioid-dependent individuals were randomized to the 0.9g or the 1.5g NTX-IMP group. All subjects exhibited significant antagonistic effects during hydromorphone challenge test. …”
    Get full text
    Article
  20. 540

    First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours by Michael Smith, Aung Naing, Todd Bauer, Kyriakos P Papadopoulos, Osama Rahma, Elena Garralda, Glenn J Hanna, Michael J Pishvaian, Xuejun Chen, Sven Gogov, Omar Saavedra, Howard Kallender, LuLu Cheng, Emil Kuriakose

    Published 2024-07-01
    “…The most common INCB001158-related AEs were fatigue (n=10/107 (9.3%)) and nausea (n=10/107 (9.3%)) with monotherapy and diarrhoea (n=24/147 (16.3%)) and fatigue (n=22/147 (15.0%)) with combination therapy. …”
    Get full text
    Article